



## Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

Jan 16, 2024

IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

For more information about the Sequire Investor Summit, including registration details, please visit the official event website at <https://puertorico.srax.com/>

### About Oncocyte

Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test. DetermaO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for assessing therapeutic efficacy. For more information, please visit: [www.oncocyte.com](http://www.oncocyte.com)

DetermaO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.

### About SRAX

SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, [Sequire](#), companies can track their investors' behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit [srax.com](http://srax.com) and [mysequire.com](http://mysequire.com)

### CONTACT

Stephanie Prince  
PCG Advisory  
(646) 863-6341  
[sprince@pcgadvisory.com](mailto:sprince@pcgadvisory.com)



Source: OncoCyte Corporation

